---
title: Adjuncts, Contraindications, and Safety Considerations
version: 1.0
last-updated: 2025-12-01
---

# Adjuncts, Contraindications, and Safety Considerations  
Robot-Assisted Total Knee Arthroplasty (rTKA) – 2025 Update

## Opioid-Free Adjuncts – Absolute & Relative Contraindications

| Agent                  | Absolute Contraindications                          | Relative / Use Caution                                 | Notes / Monitoring                                      |
|------------------------|-----------------------------------------------------|---------------------------------------------------------|------------------------------------------------------------------|
| **Ketamine**           | Acute psychosis, uncontrolled schizophrenia         | Uncontrolled hypertension (SBP >180), severe CAD, recent CVA/TIA | Avoid induction doses >0.5 mg/kg in severe CAD; psychomimetic risk low at sub-anesthetic doses |
| **Dexmedetomidine**    | High-degree AV block (2°/3° without pacemaker), HR <45 despite atropine | Baseline HR <55, hypovolemia, severe LV dysfunction    | Bradycardia usually responsive to glycopyrrolate; stop infusion if HR <50 and symptomatic |
| **Magnesium sulfate**  | Myasthenia gravis, complete heart block, CrCl <30 mL/min | CrCl 30–50 mL/min (reduce dose 25–50 %)                | Infuse over ≥15 min; monitor patellar reflexes if >8 mmol/L serum level suspected |
| **Lidocaine infusion** (block-free pathway) | Severe hepatic dysfunction, known allergy           | Heart block, CHF, weight <50 kg                         | Max 2 mg/kg/h; keep total dose <300 mg without lipid rescue prep |

## Regional Anesthesia (ACB + IPACK) – Contraindications

| Absolute                                      | Relative / Shared Decision-Making                  |
|-----------------------------------------------|----------------------------------------------------|
| Patient refusal                               | Local infection at block site                      |
| Active systemic infection / sepsis            | Chronic pain syndrome on high-dose opioids         |
| Coagulopathy or therapeutic anticoagulation outside ASRA 2024 windows | Severe spinal deformity (if considering spinal)    |
| Known allergy to local anesthetics            | Neurologic deficit in operative limb (baseline exam required) |

**ASRA 2024 Quick Reference (deep blocks including IPACK)**  
- Rivaroxaban, apixaban, edoxaban: ≥72 h (CrCl >50) / ≥120 h (CrCl <50)  
- Dabigatran: ≥72–120 h depending on CrCl  
- Warfarin: INR ≤1.4  
- Therapeutic LMWH: ≥24 h  

## Opioid-Inclusive Pathway – Relative Contraindications  
(Consider switching to OFIA + blocks if any of the following present)

- Untreated or severe OSA (STOP-Bang ≥5 + witnessed apneas)  
- Chronic respiratory disease (home O₂, severe COPD, OHS)  
- History of prolonged post-op ventilation or ICU admission after prior surgery  
- Neuromuscular disease with poor cough (e.g., ALS, advanced Parkinson’s)

## Agents to Avoid Routinely in rTKA (2024–2025 Consensus)

| Agent                     | Reason (Level of Evidence)                                 | Reference |
|---------------------------|--------------------------------------------------------------------|-----------|
| Gabapentinoids (gabapentin, pregabalin) | ↑ respiratory depression, delirium, dizziness in elderly TKA patients without added opioid-sparing benefit when modern multimodal used | Angst 2024, Memtsoudis 2023, ASA/APSF 2024 |
| Routine intraoperative opioids in opioid-naïve patients | ↑ PONV, ileus, respiratory events, delayed mobilization | Soffin 2023, ERAS Society 2020/2024 |
| High-dose dexamethasone (>10 mg) | Minimal additional benefit; small hyperglycemia risk | De Oliveira 2022, Li 2024 |
